Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:14 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 5,512 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT01620489
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Concord, California • La Jolla, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin D and Osteoporosis Prevention in Elderly African American Women

NCT01153568
View directory record Official record
Conditions
Determine Effect of Vitamin D on Bone Health in Elderly African American Women
Interventions
Vitamin D 3, placebo
Dietary Supplement · Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Nov 3, 2026, 9:14 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

NCT03126097
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

NCT02370693
View directory record Official record
Conditions
Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
Interventions
Bortezomib, Placebo, Mycophenolate mofetil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2Phase 3 Interventional

Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

NCT00927914
View directory record Official record
Conditions
Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Interventions
Ranirestat, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

NCT02947347
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Ibrutinib Oral Capsule, Placebo, Rituximab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
60 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
25
States / cities
Mobile, Alabama • Duarte, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 3, 2026, 9:14 AM EST
Withdrawn Phase 4 Interventional

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

NCT04676126
View directory record Official record
Conditions
Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions
Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 4%, SB206 8%, SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
2 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Ana, California • Thornton, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2 Interventional

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

NCT00084825
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

NCT02925117
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Tampa, Florida • Sandy Springs, Georgia • Rockville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and glyburide, Glyburide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

NCT02033109
View directory record Official record
Conditions
HIV
Interventions
PC-1005, HEC gel
Drug
Lead sponsor
Population Council
Other
Eligibility
19 Years to 49 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 1 Interventional Results available

A Study of Multiple Doses of LY2922470 in Participants With Diabetes

NCT01867216
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, LY2922470
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chula Vista, California • Eatontown, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 3, 2026, 9:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

NCT04531033
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Lactobacillus acidophilus MPH734, Placebo
Dietary Supplement
Lead sponsor
Lemuel W. Taylor IV
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

NCT03813238
View directory record Official record
Conditions
Cerebral Palsy, Dyskinetic
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2Phase 3 Interventional Results available

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

NCT01219855
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions
Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Nov 3, 2026, 9:14 AM EST
Terminated Phase 2 Interventional

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

NCT01972178
View directory record Official record
Conditions
Dyslipidemia
Interventions
PRC-4016, Placebo, Statins
Drug
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

NCT00942240
View directory record Official record
Conditions
Healthy
Interventions
ACU-4429, matching placebo tablet
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

NCT03681093
View directory record Official record
Conditions
Nasal Polyps
Interventions
Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Nov 3, 2026, 9:14 AM EST
Terminated Phase 3 Interventional Results available

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

NCT03504917
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Balovaptan, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Dothan, Alabama • Phoenix, Arizona • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Nov 3, 2026, 9:14 AM EST
Withdrawn Phase 3 Interventional

Major Depressive Disorder With Mixed Features

NCT01423240
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lurasidone 20 mg, Lurasidone 60 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
27
States / cities
Birmingham, Alabama • Imperial, California • National City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

NCT00631007
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

NCT04117711
View directory record Official record
Conditions
Classic Galactosemia
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Nov 3, 2026, 9:14 AM EST
Completed Phase 1 Interventional

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

NCT01971164
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Nov 3, 2026, 9:14 AM EST